Kepenek, F.Can, C.Komek, H.Kaplan, IGundogan, C.Ebinc, S.Guzel, Y.2024-04-242024-04-2420230928-12581878-6820https://doi.org/10.1016/j.mednuc.2022.12.001https://hdl.handle.net/11468/15809Aim of the study. - In this study, we aimed to determine the factors affecting increased glucose metabolism, which is one of the dedifferentiation mechanisms, by using [18F]FDG and [68Ga]Ga-PSMA PET/CT in patients with castration-resistant prostate cancer (CRPC).Materials and method. - Ninety-three patients with CRPC were included in the study. Gleason score (GS), and total PSA and free PSA levels of the patients were recorded. Patient-and organ-based evaluations were performed according to the lesion uptakes as follows: score 0: PSMA (-) FDG (-), score 1: PSMA (+) FDG (-), score 2: PSMA (+) FDG (+) (FDG < PSMA), score 3: PSMA (+) FDG (+) (FDG = PSMA), score 4: PSMA (+) FDG (+) (FDG > PSMA), and score 5: PSMA (-) FDG (+). scores 1 and 2 were classified as group 1, and scores 3 to 5 were classified as group 2.Results. - The median age of our patients was 70 (51-88) years. Eighty-eight patients (94.6%) were PSMA-positive, 78 patients (83.8%) were FDG-positive, and 89 patients (95.6%) were or PSMA or FDG positive. When the two groups were compared in terms of patient-based parameters, the median age and GS were found to be significantly higher in group 2. ROC analyses revealed that age and GS were significant in predicting group 2.Conclusion. - Since glucose metabolism can increase in CRPC patients with advanced age and high GS, we recommend combining [18F]FDG PET/CT with [68Ga]Ga-PSMA PET/CT in routine clinical practice in order to identify this patient subset and refer them to additional therapies. ?@ 2023 Published by Elsevier Masson SAS.eninfo:eu-repo/semantics/closedAccessPsmaPetCtProstate CancerCastration ResistanceGlucose Metabolism[18f]FdgArticle474193199WOS:0010528313000012-s2.0-8515037126210.1016/j.mednuc.2022.12.001Q4N/A